INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against Apyx Medical Corporation and Encourages Investors to Contact the Firm Before June 17

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Apr 18, 2019 08:35 pm
NEW YORK -- 

The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed in the U.S. District Court for the Middle District of Florida on behalf of those who acquired Apyx Medical Corporation (“Apyx” or the “Company”) (NASDAQ: APYX) securities during the period from August 1, 2018 through April 1, 2019 (the “Class Period”). Investors have until June 17, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The lawsuit alleges that Apyx failed to disclose to investors: (i) that the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint; (ii) that, as a result, the clinical study did not support the Company’s application for regulatory clearance; and (iii) that, as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing.

On April 1, 2019, Apyx announced that it had withdrawn its 510(k) application for Renuvion, a patented surgical device for use in dermal surgical procedures, citing concerns raised by the FDA. Apyx revealed that the FDA had questioned the device’s clinical results, which differed greatly from two of the investigational centers used in the study, as well as the potential impact of certain protocol deviations.

On this news, shares of Apyx fell $2.49 per share, approximately 35.8%, to close at $4.46 on April 2, 2019.

If you acquired Apyx securities, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney LLP at 212-371-6600, by email at [email protected], or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kirby McInerney LLP
Thomas W. Elrod, Esq., (212) 371-6600
[email protected]
www.kmllp.com

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).